darzalex faspro - daratumumab and hyaluronidase - fihj
(Daratumumab And Hyaluronidase-Fihj (Human Recombinant))Janssen Biotech, Inc.
Usage: DARZALEX FASPRO treats adult patients with multiple myeloma (newly diagnosed or relapsed/refractory, across various combination regimens), high-risk smoldering multiple myeloma, and newly diagnosed light chain (AL) amyloidosis. Not recommended for AL amyloidosis with NYHA Class IIIB/IV cardiac disease outside clinical trials.